» Articles » PMID: 11742877

Tumor Necrosis Factor Receptor Superfamily 14 is Involved in Atherogenesis by Inducing Proinflammatory Cytokines and Matrix Metalloproteinases

Overview
Date 2001 Dec 18
PMID 11742877
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor necrosis factor (TNF) receptor superfamily 14 (TNFRSF14) is the cellular receptor for TNF superfamily 14 (LIGHT). Immunohistochemical staining of human carotid atherosclerotic plaques revealed a high level of expression of the TNFRSF14 in regions rich in macrophages/foam cells. To investigate the role of TNFRSF14 in the functioning of monocytes in relation to atherogenesis, we have analyzed TNFRSF14 expression levels and cellular events after stimulation of TNFRSF14 in peripheral blood monocytes or the human macrophage-like cell line, THP-1. A high level of expression of TNFRSF14 was detected in activated monocytes, in macrophages derived from monocytes, and in THP-1 cells. Concomitant activation of THP-1 cells with interferon-gamma and immobilized anti-TNFRSF14 monoclonal antibody resulted in synergistic induction of proatherogenic cytokines, such as TNF-alpha and interleukin-8. Activation of THP-1 cells with immobilized anti-TNFRSF14 monoclonal antibody induced expression of matrix metalloproteinase (MMP)-1, MMP-9, MMP-13, and tissue inhibitors of metalloproteinase-1 and -2. Furthermore, immunohistochemical staining of atherosclerotic plaques with severe infiltration of foam cells revealed that the expression patterns of TNFRSF14 and MMP-1, -9, and -13 overlapped. Treatment of THP-1 cells with soluble LIGHT also caused induction of MMP-9 and interleukin-8. These data suggest that TNFRSF14 is involved in atherosclerosis via the induction of proatherogenic cytokines and decreasing plaque stability by inducing extracellular matrix-degrading enzymes.

Citing Articles

Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4Foxp3 Regulatory T Cell Immunosuppression.

Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K Int J Drug Discov Pharm. 2025; 3(4).

PMID: 39926714 PMC: 11804271. DOI: 10.53941/ijddp.2024.100022.


New cardiovascular disease markers in patients with familial hypercholesterolemia carriers of genetic variants.

de Paiva Silvino J, Jannes C, Pestana R, de Paiva Silvino L, Silva I, Gomes K J Diabetes Metab Disord. 2024; 24(1):13.

PMID: 39697859 PMC: 11649891. DOI: 10.1007/s40200-024-01537-w.


Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma.

Liu Y, Ye S, He S, Chi D, Wang X, Wen Y Nat Commun. 2024; 15(1):7713.

PMID: 39231979 PMC: 11375053. DOI: 10.1038/s41467-024-52153-4.


Protein Identification for Stroke Progression via Mendelian Randomization in Million Veteran Program and UK Biobank.

Elmore A, Adhikari N, Hartley A, Aparicio H, Posner D, Hemani G Stroke. 2024; 55(8):2045-2054.

PMID: 39038097 PMC: 11259242. DOI: 10.1161/STROKEAHA.124.047103.


Herpesvirus Entry Mediator as an Immune Checkpoint Target and a Potential Prognostic Biomarker in Myeloid and Lymphoid Leukemia.

Basingab F, Alzahrani R, Alrofaidi A, Barefah A, Hammad R, Alahdal H Biomolecules. 2024; 14(5).

PMID: 38785930 PMC: 11117912. DOI: 10.3390/biom14050523.